Hydrofarm vs Omega Flex
HYFM and OFLX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HYFM and OFLX compare
Omega Flex is the larger company, worth 68 times as much as Hydrofarm ($218M against $3.2M).
Omega Flex grew revenue faster over the last twelve months (−2.0% versus −34.1% for Hydrofarm).
Omega Flex keeps more of each dollar of sales as profit, with a net margin of 10.7% compared with −267% at Hydrofarm.
Omega Flex pays a dividend yielding 6.3%; Hydrofarm does not pay one.
Omega Flex scores higher on the StockData Score (18 against 1 for Hydrofarm), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HYFM | OFLX |
|---|---|---|
| Size and price | ||
| Market cap | $3.2M | $218M |
| Share price | $0.664 | $21.64 |
| Change, 1 year | −60.3% | −18.7% |
| Change, 5 years | −99.8% | −83.2% |
| Beta (5Y) | 2.58 | 0.86 |
| Employees | 251 | 172 |
| StockData Score | ||
| Total score | 1 | 18 (better) |
| Valuation score | 1 | 6 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 20.6× |
| P/S | 0.0× (better) | 2.2× |
| P/B | – | 2.7× |
| EV/EBITDA | – | 13.2× |
| P/FCF | – | 30.9× |
| FCF yield | −165% | 3.2% (better) |
| Fair value | – | $28.23 |
| Margin of safety | – | 23.4% |
| Growth | ||
| Revenue growth (TTM) | −34.1% | −2.0% (better) |
| Revenue growth, 5Y average | −17.1% | −1.5% (better) |
| Net income growth (TTM) | – | −34.6% |
| EPS growth (TTM) | – | −34.0% |
| EPS growth, 5Y average | – | −5.7% |
| Profitability | ||
| Gross margin | 9.4% | 55.6% (better) |
| Operating margin | −253% | 12.2% (better) |
| Net margin | −267% | 10.7% (better) |
| FCF margin | −5.0% | 7.2% (better) |
| Return on equity | −536% | 12.7% (better) |
| Return on invested capital | −135% | 24.4% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −16.8× | – |
| Current ratio | 0.27 | 5.36 (better) |
| Altman Z-score | −20.98 | 9.87 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 6.3% |
| Payout ratio | – | 130% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 4.0% |
| Shareholder yield | 0.00% | 6.3% (better) |
| Ownership | ||
| Held by institutions | 6.3% | 30.7% |
| Held by insiders | 26.5% | 48.2% |
| Insider net buying, 12 months | $12.6K | $193K (better) |
| Short interest, % of float | 14.5% | 2.2% |
Go deeper
- HYFM stock overview
- HYFM income statement
- HYFM valuation and score
- OFLX stock overview
- OFLX income statement
- OFLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.